Sarah Cannon Research Institute (SCRI)

A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial (2025) Hortobagyi GN, Lacko A, Sohn J, Cruz F, Ruiz Borrego M, Manikhas A, Hee Park Y, et al. Journal article A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study (2024) Neven P, Stahl N, Vidal M, Martín M, Kaufman PA, Harbeck N, Hunt KK, et al. Journal article Ribociclib plus Endocrine Therapy in Early Breast Cancer (2024) Slamon D, Lipatov O, Nowecki Z, McAndrew N, Kukielka-Budny B, Stroyakovskiy D, Yardley DA, et al. Journal article Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial (2023) Rugo HS, Im SA, Cardoso F, Cortes J, Curigliano G, Musolino A, Pegram MD, et al. Journal article Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer (2023) Slamon DJ, Fasching P, Hurvitz S, Chia S, Crown J, Martín M, Barrios CH, et al. Journal article Matching adjusted indirect comparison of PFS & OS comparing ribociclib plus letrozole vs palbociclib plus letrozole as first-line treatment of HR+/HER2-ABC: Analysis based on updated PFS & final OS results of MONALEESA-2 & PALOMA-2 (2022) Jhaveri K, O'Shaughnessy J, Fasching P, Cardoso F, Tolaney S, Hamilton E, Sharma VK, et al. Conference contribution Longitudinal stability of molecular alterations and drug response profiles in tumor spheroid cell lines enables reproducible analyses (2021) Nickel AC, Picard D, Qin N, Wolter M, Kaulich K, Hewera M, Pauck D, et al. Journal article Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group (2021) Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, et al. Journal article, Review article Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane (2021) O'Shaughnessy J, Schwartzberg L, Piccart M, Rugo HS, Yardley DA, Cortes J, Untch M, et al. Conference contribution International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders (2019) Hillengass J, Usmani S, Rajkumar SV, Durie BG, Mateos MV, Lonial S, Joao C, et al. Journal article, Review article